Oncoclinicas do Brasil Servicos Medicos SA Statistics
Oncoclinicas do Brasil Servicos Medicos SA (ONCO3) Stock Statistics & Valuation Metrics
Total Valuation
Oncoclinicas do Brasil Servicos Medicos SA has a market cap or net worth of BRL 919.27M. The enterprise value is BRL 4.56B.
- Market Cap
- BRL 919.27M
- Enterprise Value
- BRL 4.56B
Share Statistics
Oncoclinicas do Brasil Servicos Medicos SA has 1,135,097,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,135,097,800
- Owned by Insiders
- ―
- Owned by Institutions
- 5.29%
Financial Efficiency
Oncoclinicas do Brasil Servicos Medicos SA’s return on equity (ROE) is -4.02 and return on invested capital (ROIC) is -47.87%.
- Return on Equity (ROE)
- -4.02
- Return on Assets (ROA)
- -0.51
- Return on Invested Capital (ROIC)
- -47.87%
- Return on Capital Employed (ROCE)
- -1.28
- Revenue Per Employee
- 880.81K
- Profits Per Employee
- -556.14K
- Employee Count
- 6,516
- Asset Turnover
- 0.80
- Inventory Turnover
- 21.31
Valuation Ratios
The current PE Ratio of Oncoclinicas do Brasil Servicos Medicos SA is -0.12. Oncoclinicas do Brasil Servicos Medicos SA’s PEG ratio is 0.00.
- PE Ratio
- -0.12
- PS Ratio
- 0.16
- PB Ratio
- 28.14
- Price to FCF
- 4.34
- Price to Operating Cash Flow
- 1.47
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Oncoclinicas do Brasil Servicos Medicos SA had revenue of 5.74B and earned -3.62B in profits. Earnings per share was -5.38.
- Revenue
- 5.74B
- Gross Profit
- 1.79B
- Operating Income
- -2.47B
- Pretax Income
- -3.16B
- Net Income
- -3.62B
- EBITDA
- -2.23B
- Earnings Per Share (EPS)
- -5.38
Cash Flow
In the last 12 months, operating cash flow was 315.69M and capital expenditures -131.92M, giving a free cash flow of 183.77M billion.
- Operating Cash Flow
- 315.69M
- Free Cash Flow
- 183.77M
- Free Cash Flow per Share
- 0.28
Dividends & Yields
Oncoclinicas do Brasil Servicos Medicos SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 23.06%
- Earnings Yield
- -900.30%
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- -65.22%
- 50-Day Moving Average
- 1.01
- 200-Day Moving Average
- 1.34
- Relative Strength Index (RSI)
- 37.92
- Average Volume (3m)
- 16.23M
Important Dates
Oncoclinicas do Brasil Servicos Medicos SA upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Oncoclinicas do Brasil Servicos Medicos SA as a current ratio of 0.56, with Debt / Equity ratio of 421.66%
- Current Ratio
- 0.56
- Quick Ratio
- 0.52
- Debt to Market Cap
- 1.80
- Net Debt to EBITDA
- -1.48
- Interest Coverage Ratio
- -3.88
Taxes
In the past 12 months, Oncoclinicas do Brasil Servicos Medicos SA has paid 508.46M in taxes.
- Income Tax
- 508.46M
- Effective Tax Rate
- -0.16
Enterprise Valuation
Oncoclinicas do Brasil Servicos Medicos SA EV to EBITDA ratio is -1.77, with an EV/FCF ratio of 24.33.
- EV to Sales
- 0.90
- EV to EBITDA
- -1.77
- EV to Free Cash Flow
- 24.33
- EV to Operating Cash Flow
- 14.16
Balance Sheet
Oncoclinicas do Brasil Servicos Medicos SA has BRL 145.27M in cash and marketable securities with BRL 3.82B in debt, giving a net cash position of -BRL 3.67B billion.
- Cash & Marketable Securities
- BRL 145.27M
- Total Debt
- BRL 3.82B
- Net Cash
- -BRL 3.67B
- Net Cash Per Share
- -BRL 3.23
- Tangible Book Value Per Share
- -BRL 3.84
Margins
Gross margin is 30.28%, with operating margin of -55.05%, and net profit margin of -83.55%.
- Gross Margin
- 30.28%
- Operating Margin
- -55.05%
- Pretax Margin
- -77.35%
- Net Profit Margin
- -83.55%
- EBITDA Margin
- -50.72%
- EBIT Margin
- -56.61%
Analyst Forecast
The average price target for Oncoclinicas do Brasil Servicos Medicos SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -18.97%
- EPS Growth Forecast
- -260.38%

